News 
Market Data 
Discover
Replies to post #326783 on Anavex Life Sciences Corp (AVXL)
Comparisons between Fmr1 KO2 groups demonstrated a signicant reduction in total distance traveled (number of squares crossed in 3 min) by the blarcamesine-treated animals with respect to vehicle-treated mice (Student’s t-test p = 0.0006). The relevance of these changes was conrmed by comparing vehicletreated Fmr1 KO2 mice to their WT counterparts, since the former displayed an increase in the abovementioned measure of hyperactivity (p < 0.001). When all 4 mouse groups were contrasted, chronic treatment with blarcamesine signicantly reduced the behavior in Fmr1 KO2 mice to levels indistinguishable from those observed in vehicle-treated WT mice (Fig. 1a).
